Overview

Pentoxifylline and Tocopherol (PENTO) in the Treatment of Medication-related Osteonecrosis of the Jaw (MRONJ)

Status:
Enrolling by invitation

Trial end date:
2023-01-01

Target enrollment:

Participant gender:

Summary

The overall purpose of this project is to answer the following clinical question: Among Medication-Related Osteonecrosis of the Jaw (MRONJ) patients, do those who are treated with the Pentoxifylline and Tocopherol (PENTO) regimen and standard of care, when compared to those treated with standard of care alone, have decreased areas of exposed bone after one year of treatment?

Phase:

Phase 3

Details

Lead Sponsor:

University of Washington

Collaborators:

New York Center for Orthognathic and Maxillofacial Surgery
Oregon Health and Science University
University of Alabama at Birmingham
University of Michigan

Treatments:

alpha-Tocopherol
Pentoxifylline
Tocopherols
Tocotrienols
Vitamin E
Vitamins